 |
MR Vol.13 No.3 indexに戻る
 |
MODERN RHEUMATOLOGY
Vol.13 No.3 |
 |
|
|
 |
|
|
CD26: a key molecule in immune regulation
and autoimmune diseases
|
|
|
| Osamu Hosono1, Kei Ohnuma2, Nam H. Dang3 and
Chikao Morimoto2 |
(1) Rheumatology Clinic, Research Hospital, Institute
of Medical Science, University of Tokyo, Tokyo, Japan
(2) Division of Clinical Immunology, Advanced Clinical Research Center, Institute
of Medical Science, University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo,
108-8639, Japan
(3) Department of Lymphoma/Myeloma, MD Anderson Cancer Center, Houston, TX,
USA |
| |
| Received: 30 November 2002 Accepted: 18 January
2003 |
| |
| Abstract |
| In this review, we focus on major aspects of
the biology of CD26, a dipeptidyl peptidase IV (DPPIV)-containing
surface glycoprotein with multiple functions. In particular, we discuss
findings demonstrating that CD26/DPPIV has an essential role in immune
regulation as a T cell activation molecule and a regulator of chemokine
function. We also review recent studies that identify key cellular
molecules that physically associate with CD26 and the potential consequences
of their interaction, including those with clinically related implications.
Furthermore, we present work suggesting a role for CD26 in the pathophysiology
of immune-mediated disorders as well as autoimmune diseases. We present
recent studies that investigate the potential role of CD26 as a molecular
target for novel treatment modalities for immune-mediated diseases,
with work involving the use of anti-CD26 monoclonal antibody, DPPIV
inhibitors, and soluble CD26 molecules. |
| |
| Key words |
| Autoimmune disease - CD26 - Cell cycle arrest
- Dipeptidyl peptidase IV (DPPIV) - T cell activation |
|
|
 |
|
|
